Avicanna Inc. (AVCNF)
| Market Cap | 10.92M -52.4% |
| Revenue (ttm) | 17.83M -0.2% |
| Net Income | -2.63M |
| EPS | -0.02 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 68,500 |
| Open | 0.0836 |
| Previous Close | 0.0835 |
| Day's Range | 0.0836 - 0.0863 |
| 52-Week Range | 0.0684 - 0.2363 |
| Beta | 0.35 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 13, 2026 |
About Avicanna
Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research, development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for medical and pharmaceutical markets in Canada and internationally. It provides medical cannabis formulary products, including oral, sublingual, topical, and transdermal deliveries with various ratios of cannabinoids under the RHO Phyto brand; and indication-specific cannabinoid-based candidates to address unmet medical needs in the areas of dermatol... [Read more]
Financial Performance
In 2025, Avicanna's revenue was 25.48 million, an increase of 0.08% compared to the previous year's 25.46 million. Losses were -2.76 million, -39.75% less than in 2024.
Financial numbers in CAD Financial StatementsNews
Avicanna Launches MyMedi.ca Integrated Healthcare Program in Canada
Integrating MyMedi.ca healthcare provider-guided medical cannabis care into hospitals, specialty clinics, insurers and multidisciplinary healthcare networks in Canada Integrating MyMedi.ca healthcare ...
Avicanna Announces Closing of Strategic Non-Brokered Private Placement
Strategic investment by pharmaceutical executive and life sciences investor Michael Porter Strategic investment by pharmaceutical executive and life sciences investor Michael Porter
Avicanna Registration statement: Q2 2026
Avicanna filed a registration statement on August 14, 2026, providing details about a securities offering with the SEC.
Avicanna Registration statement: Q2 2026
Avicanna filed a registration statement on August 14, 2026, providing details about a securities offering with the SEC.
Avicanna Earnings release: Q2 2026
Avicanna released its Q2 2026 earnings on August 14, 2026, summarizing the period's financial results.
Avicanna Reports Q2 2026 Financial Results
Gross margin improves to 57%, supported by 48% quarterly growth in proprietary product sales QUIX™ rapid-onset portfolio prepared for Q3 launch with more than 35 commercial listings secured
Avicanna Introduces QUIX™ Rapid-Onset Medical Cannabis Portfolio
Initial Medical Cannabis SKUs, Including Rapid-Onset Capsules and Soft Chews, Planned for Q3 2026 Improving Patient Access with Accurately Dosed, Rapid-Onset and Non-Combustible Formats
Avicanna Announces Promotion of Nick Hilborn CPA CA to Chief Financial Officer
TORONTO, June 30, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commer...
Splash Beverage Group Invests in Avicanna, a Leading Cannabinoid Biopharmaceutical Platform, Advancing Its Transformation Into Cannabinoid Healthcare
FORT LAUDERDALE, Fla., June 15, 2026 (GLOBE NEWSWIRE) -- Splash Beverage Group, Inc. (NYSE American: SBEV) today announced the completion of a CDN$300,000 strategic investment in Avicanna Inc. (TSX: A...
Avicanna Announces Closing of Non-Brokered Private Placement
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LA...
Avicanna Earnings release: Q1 2026
Avicanna released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
Avicanna Registration statement: Q1 2026
Avicanna filed a registration statement on May 14, 2026, providing details about a securities offering with the SEC.
Avicanna Registration statement: Q1 2026
Avicanna filed a registration statement on May 14, 2026, providing details about a securities offering with the SEC.
Avicanna Reports Q1 2026 Financial Statements
Record revenue and gross profits driven by Canadian commercial growth and proprietary product expansion Continued advancement of pharmaceutical pipeline, medical affairs initiatives and international ...
Avicanna Announces Results of Annual General and Special Meeting
TORONTO, May 08, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commerc...
Avicanna Transcript: AGM 2026
The meeting confirmed strong financial improvements in 2025, including higher gross margins, reduced net loss, and positive adjusted EBITDA in Q4. All board nominees and proposals, including the incentive plan, were approved, and strategic focus remains on Canadian, U.S., and international expansion.
Avicanna announces McCormack tendered her resignation as member of board
Avicanna (AVCNF) announces that Eileen McCormack, who was not on the slate of directors for re-election or election as outlined in the circular at the upcoming annual general and special…
Avicanna Announces Change in Board of Directors
TORONTO, May 01, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and com...
Avicanna Welcomes Initial U.S. Rescheduling of Medical Cannabis & Provides Scientific Update
Rescheduling aligns with Avicanna's established pharmaceutical and medical cannabis strategyRescheduling further supports advancement of R&D, clinical development, and medical affairs initiatives
Annual General and Special Meeting of Shareholders to be held May 7, 2026
TORONTO, April 21, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and c...
Avicanna Earnings Call Transcript: Q4 2025
Revenue reached CAD 25.5 million with a 53% gross margin and near break-even adjusted EBITDA. Expanded to 24 international markets, launched new proprietary drug delivery technologies, and improved operational efficiency. Positioned for further growth and U.S. market entry in 2026.
Avicanna Earnings release: Q4 2025
Avicanna released its Q4 2025 earnings on April 7, 2026, summarizing the period's financial results.
Avicanna Registration statement: Q4 2025
Avicanna filed a registration statement on April 7, 2026, providing details about a securities offering with the SEC.
Avicanna Registration statement: Q4 2025
Avicanna filed a registration statement on April 7, 2026, providing details about a securities offering with the SEC.
Avicanna Announces Changes to its Board of Directors
TORONTO, April 06, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and ...